logo-loader
viewQ BioMed Inc.

Q BioMed CEO sees significant capital funding for next 3 years

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive announced that its technology partner, Mannin Research Inc, has received a $7.5 million grant from the German state of Saxony to fund the development of its glaucoma therapies.

Corin talked about how the two partners plan to accelerate the pre-clinical efforts of its two approaches to prevent glaucoma.

Quick facts: Q BioMed Inc.

Price: 1.87 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $42.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zanaga Iron Ore's Andrew Trahar updates on floating port facility and early...

Zanaga Iron Ore Company Limited's (LON:ZIOC) Andrew Trahar speaks to Proactive London following the news it's completed a concept study to assess the viability of a floating dewatering, storage and offloading port facility at its project in the Republic of Congo. He says the study indicates the...

2 days, 10 hours ago

2 min read